SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques-Reference-Cited by-同舟云学术

SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques

Published:2022-03-18 Issue:11 Volume:8 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Dalvie Neil C.¹²^ORCID,Tostanoski Lisa H.³^ORCID,Rodriguez-Aponte Sergio A.²⁴^ORCID,Kaur Kawaljit⁵^ORCID,Bajoria Sakshi⁵^ORCID,Kumru Ozan S.⁵^ORCID,Martinot Amanda J.³⁶^ORCID,Chandrashekar Abishek³^ORCID,McMahan Katherine³^ORCID,Mercado Noe B.³^ORCID,Yu Jingyou³^ORCID,Chang Aiquan³⁷^ORCID,Giffin Victoria M.³^ORCID,Nampanya Felix³^ORCID,Patel Shivani³^ORCID,Bowman Lesley⁸^ORCID,Naranjo Christopher A.²,Yun Dongsoo²,Flinchbaugh Zach⁹,Pessaint Laurent⁹^ORCID,Brown Renita⁹,Velasco Jason⁹,Teow Elyse⁹,Cook Anthony⁹,Andersen Hanne⁹^ORCID,Lewis Mark G.⁹^ORCID,Camp Danielle L.²,Silverman Judith Maxwell¹⁰^ORCID,Nagar Gaurav S.¹¹,Rao Harish D.¹¹,Lothe Rakesh R.¹¹,Chandrasekharan Rahul¹¹,Rajurkar Meghraj P.¹¹,Shaligram Umesh S.¹¹,Kleanthous Harry¹²^ORCID,Joshi Sangeeta B.⁵,Volkin David B.⁵,Biswas Sumi⁸¹³,Love J. Christopher¹²¹⁴^ORCID,Barouch Dan H.³⁷¹⁴¹⁵^ORCID

Affiliation:

1. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

2. The Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

3. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

4. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

5. Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.

6. Departments of Infectious Diseases and Global Health and Comparative Pathobiology, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA.

7. Harvard Medical School, Boston, MA 02115, USA.

8. SpyBiotech Limited, Oxford Business Park North, Oxford OX4 2JZ, UK.

9. Bioqual, Rockville, MD 20852, USA.

10. Bill and Melinda Gates Medical Research Institute, Cambridge, MA 02139, USA.

11. Serum Institute of India Pvt. Ltd., Pune, India.

12. Bill and Melinda Gates Foundation, Seattle, WA 98109, USA.

13. The Jenner Institute, University of Oxford, Oxford OX3 7DQ, UK.

14. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.

15. Massachusetts Consortium on Pathogen Readiness, Boston, MA 02115, USA.

Abstract

Authorized vaccines against SARS-CoV-2 remain less available in low- and middle-income countries due to insufficient supply, high costs, and storage requirements. Global immunity could still benefit from new vaccines using widely available, safe adjuvants, such as alum and protein subunits, suited to low-cost production in existing manufacturing facilities. Here, a clinical-stage vaccine candidate comprising a SARS-CoV-2 receptor binding domain–hepatitis B surface antigen virus–like particle elicited protective immunity in cynomolgus macaques. Titers of neutralizing antibodies (>104) induced by this candidate were above the range of protection for other licensed vaccines in nonhuman primates. Including CpG 1018 did not significantly improve the immunological responses. Vaccinated animals challenged with SARS-CoV-2 showed reduced median viral loads in bronchoalveolar lavage (~3.4 log10) and nasal mucosa (~2.9 log10) versus sham controls. These data support the potential benefit of this design for a low-cost modular vaccine platform for SARS-CoV-2 and other variants of concern or betacoronaviruses.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference46 articles.

1. SARS-CoV-2 Vaccines

2. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

3. COVID-19 dynamics after a national immunization program in Israel

4. India’s massive COVID surge puzzles scientists

5. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses;Nature Nanotechnology;2024-05-06

2. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice;European Journal of Pharmaceutics and Biopharmaceutics;2023-11

3. Large-Scale Purification and Characterization of Recombinant Receptor-Binding Domain (RBD) of SARS-CoV-2 Spike Protein Expressed in Yeast;Vaccines;2023-10-16

4. Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines;Vaccine;2023-10

5. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases;Virologica Sinica;2023-10